Gemigliptin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Gemigliptin
Accession Number
DB12412
Type
Small Molecule
Groups
Investigational
Description

Gemigliptin is under investigation in Type 2 Diabetes Mellitus. Gemigliptin has been investigated for the treatment of Cancer and Cisplatin Adverse Reaction.

Structure
Thumb
Synonyms
Not Available
External IDs
LC-15-0444 / LC-150444 / LC15-0444
Categories
UNII
5DHU18M5D6
CAS number
911637-19-9
Weight
Average: 489.37
Monoisotopic: 489.141100176
Chemical Formula
C18H19F8N5O2
InChI Key
ZWPRRQZNBDYKLH-VIFPVBQESA-N
InChI
InChI=1S/C18H19F8N5O2/c19-16(20)3-1-12(32)31(8-16)6-9(27)5-13(33)30-4-2-10-11(7-30)28-15(18(24,25)26)29-14(10)17(21,22)23/h9H,1-8,27H2/t9-/m0/s1
IUPAC Name
1-[(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5,5-difluoropiperidin-2-one
SMILES
N[C@H](CN1CC(F)(F)CCC1=O)CC(=O)N1CCC2=C(C1)N=C(N=C2C(F)(F)F)C(F)(F)F

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2,4-thiazolidinedioneThe risk or severity of hypoglycemia can be increased when 2,4-thiazolidinedione is combined with Gemigliptin.
5-(2-methylpiperazine-1-sulfonyl)isoquinolineThe therapeutic efficacy of Gemigliptin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Gemigliptin.
AcarboseThe risk or severity of hypoglycemia can be increased when Acarbose is combined with Gemigliptin.
AcetazolamideThe therapeutic efficacy of Gemigliptin can be increased when used in combination with Acetazolamide.
AcetohexamideGemigliptin may increase the hypoglycemic activities of Acetohexamide.
Acetyl sulfisoxazoleThe therapeutic efficacy of Gemigliptin can be increased when used in combination with Acetyl sulfisoxazole.
Acetylsalicylic acidThe risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Gemigliptin.
AgmatineThe risk or severity of hypoglycemia can be increased when Agmatine is combined with Gemigliptin.
AICA ribonucleotideThe risk or severity of hypoglycemia can be increased when AICA ribonucleotide is combined with Gemigliptin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
11953153
PubChem Substance
347828657
ChemSpider
10127461
ChEBI
134731
ChEMBL
CHEMBL3707235
Wikipedia
Gemigliptin
ATC Codes
A10BH06 — GemigliptinA10BH52 — Gemigliptin and rosuvastatinA10BD18 — Metformin and gemigliptin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentType 2 Diabetes Mellitus1
1CompletedNot AvailableHealthy Volunteers2
1CompletedOtherHealthy Male Volunteers1
1CompletedTreatmentHealthy Volunteers5
1CompletedTreatmentHepatic Impairment1
1CompletedTreatmentType 2 Diabetes Mellitus1
1Enrolling by InvitationTreatmentHealthy Volunteers1
1Not Yet RecruitingTreatmentType 2 Diabetes Mellitus1
2, 3RecruitingTreatmentCisplatin Adverse Reaction / Malignancies1
3CompletedTreatmentType 2 DM Patients With Moderate or Severe Renal Impairment1
3CompletedTreatmentType 2 Diabetes Mellitus4
3Not Yet RecruitingTreatmentType 2 Diabetes Mellitus1
4CompletedTreatmentType 2 Diabetes Mellitus2
4RecruitingTreatmentAcarbose / Endothelial Function / Gemigliptin / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableType 2 Diabetes Mellitus1
Not AvailableCompletedBasic ScienceType 2 Diabetes Mellitus1
Not AvailableRecruitingTreatmentDiabetes Mellitus (DM)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.084 mg/mLALOGPS
logP2.02ALOGPS
logP1.72ChemAxon
logS-3.8ALOGPS
pKa (Strongest Basic)8.33ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area92.42 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity97.25 m3·mol-1ChemAxon
Polarizability39.04 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as beta amino acids and derivatives. These are amino acids having a (-NH2) group attached to the beta carbon atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Beta amino acids and derivatives
Alternative Parents
Pyridopyrimidines / Piperidinones / Delta lactams / Pyrimidines and pyrimidine derivatives / Tertiary carboxylic acid amides / Heteroaromatic compounds / Azacyclic compounds / Organofluorides / Organic oxides / Monoalkylamines
show 3 more
Substituents
Beta amino acid or derivatives / Pyridopyrimidine / Delta-lactam / Piperidinone / Piperidine / Pyrimidine / Heteroaromatic compound / Tertiary carboxylic acid amide / Carboxamide group / Lactam
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 16:17 / Updated on June 04, 2019 07:38